The agreement follows successful product sample deliveries from Thor Medical’s pilot facility at Herøya Industrial Park to Node Pharma and supports further expansion of Node Pharma’s development pipeline for alpha-emitting therapies, the companies state. Radium-224 and lead-212, together with thorium-228, are part of Thor Medical’s portfolio of products.

“The agreement is a further validation of our capabilities to deliver high-quality products from our facility at Herøya, but most importantly it confirms a market trend we have observed over time, namely the growing demand for isotopes such as radium-224 and lead-212. With Node Pharma as a partner, we are supporting an exciting development program while gaining valuable insight into future product needs,” says Jasper C. Kurth, CEO of Thor Medical.

“Reliable isotope supply is a critical enabler for our pipeline strategy. This agreement with Thor Medical broadens our access to key alpha-emitting isotopes and supports the continued expansion of our alpha pipeline,” says Erik Mjåland, Chief Business Officer and Co-founder of Node Pharma.